New radioactive drug aims to calm cancer bone pain
NCT ID NCT07197645
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a single dose of TLX090-Tx, a radioactive drug, in 33 adults with advanced cancer that has spread to the bones and causes pain. The goal is to find a safe dose and see if it can reduce pain. Participants must have at least one painful bone spot and have tried other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TLX090-Tx (153Sm-DOTMP)
What this could lead to
If it works, this could provide a new option to reduce severe bone pain in people with advanced cancer that has spread to the bones.
What could go wrong
This is a very early Phase 1 trial with only 33 people, so it is mainly checking safety and dosing. It may not reduce pain, and there could be side effects like low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE METASTASES IN SUBJECTS WITH ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Biogenix Molecular, LLC, CIRA Health
RECRUITINGMiami, Florida, 33165, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Excel Diagnostics and Nuclear Oncology Center
RECRUITINGHouston, Texas, 77042, United States
Contact Email: •••••@•••••
Contact
-
Houston Metro Urology
RECRUITINGHouston, Texas, 77027, United States
Contact Email: •••••@•••••
Contact
-
NovaCure
RECRUITINGMiami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Oncology Consultants
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
-
University of Texas Medical Branch at Galveston (UTMB)
RECRUITINGHouston, Texas, 77555, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••